소장자료

Analysis on circulating sclerostin level according to estrogen status and investigation of the relationship between the factors of bone metabolism with sclerostin

  • 김원진
  • Graduate School, Yonsei University
  • 2012
Analysis on circulating sclerostin level according to estrogen status and investigation of the relationship between the factors of bone metabolism with sclerostin
  • 자료유형
    학위논문
  • 서명/저자사항
    Analysis on circulating sclerostin level according to estrogen status and investigation of the relationship between the factors of bone metabolism with sclerostin=여성호르몬 상태에 따른 혈청 스클레로스틴의 변화와 골대사 관련인자와의 상관관계 분석/Wonjin Kim.
  • 발행사항
    Seoul : Graduate School, Yonsei University, 2012.
  • 개인저자
    김원진
  • 형태사항
    17 p. : ill ; 26 cm.
  • 일반주기
    지도교수: Yumie Rhee
  • 학위논문주기
    학위논문(석사) --Graduate School, Yonsei University :Dept. of Medicine,2012.8
  • 비통주제명
    스클레로스틴, 유방암, 아로마타제 억제제
  • 언어
    영어

소장사항

소장정보
번호 소장처 청구기호 도서상태 반납예정일 신청/예약
1 연세의학도서관/학위논문서가/교내공개(PDF) T 대출불가(별치) -

초록

Bone formation and resorption is a complicated pathway that is involved by many mediators. There is a substance called sclerostin which is secreted by osteocytes, and acts on Wnt pathway leading to inhibition of bone formation. Many studies revealed that sclerostin is elevated in postmenopausal women, and with aging and the immobilization, and is decreased in primary hyperparathyroidism, estrogen or raloxifene treated patients after menopause. Aromatase inhibitor (AI) which reduces the conversion to estrogen is used in treatment of endocrine responsive breast cancer. As it lowers estrogen level, thus bone resorption and bone turnover rate are increased. The objective of the study was to analyze the changes in serum sclerostin levels in Korean women with endocrine-responsive breast cancer who were treated with AI and assess its relationship to absolute deficient estradiol, bone turnover markers and bone mineral density (BMD). We included postmenopausal women with endocrine-responsive breast cancer (n=90) treated with AI comparing with healthy premenopausal women (n=36). Patients with breast cancer were randomly assigned to take either 5 mg alendronate with 0.5 µg of calcitriol (n=46) or placebo (n=44) for 6 months. We analyzed serum sclerostin levels by along with routine chemistry, bone turnover markers including C-telopeptide (CTx) and osteocalcin, and BMD by dual X-ray absorptiometry. Premenopausal women were 28.0 years in average and postmenopausal women were 57.7 years in average. Postmenopausal women represented significantly higher sclerostin level compared with premenopausal women (27.8 ± 13.6 vs. 23.1 ± 4.8 pmol/L, p < 0.05). Baseline sclerostin was positively correlated with either lumbar spine or total hip BMD only in postmenopausal women (r = 0.218, and r = 0.233, p < 0.05, respectively). There were no significant correlations with other bone markers. Serum sclerostin levels increased 38.7% after the use of AI in placebo group compared to the alendronate group which showed slightly lesser increase about 24.4%. In our study, serum sclerostin level is increased along the absolute deficiency of residual estrogen in postmenopausal women with endocrine-responsive breast cancer on AI therapy. It significantly correlates with BMD at all sites with statistical significance. There need to be further studies in large numbers.